Nasdaq News
Commercial Launch Announcement Marks a New Chapter for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) — FDA-Approved Preservative-Free Ketamine Now Being Sold, 17-Person National Sales Team Activated, Market Relationships Cover Approximately 80% of U.S. Ke
From National Security to Global Enterprise Media, Cyabra $CYAB Is Expanding Its Commercial Footprint as Demand for AI-Powered Digital Intelligence Accelerates
Major Solar Infrastructure Surveying Awards, a Multi-Billion-Dollar Grid Upgrade, 31 DaaS Acquisitions and Targeted 40%–60% Profit Margins Highlight a Company Building Serious Commercial Momentum
Genprex, Inc. (N A S D A Q: GNPX) Provides New Clinical Patient Analysis Uncovers Promising TUSC2-Associated Biological Activity Involving Mitochondrial Function, Cellular Repair, Autophagy and Protein Quality Control. Combined With the Roche Diagnostics
Strategic Roche Diagnostics Partnership, New Biomarker Findings and Expanding Clinical Research Could Help Transform Patient Selection for Non-Small Cell Lung Cancer Treatment, While Genprex, Inc. (N A S D A Q: GNPX) Advances Additional Opportunities in S
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Also Received an $11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression
31 DaaS Acquisitions, 425% First-Half Revenue Growth, Expanding International Operations and a Growing AI Technology Portfolio Put ZenaTech, Inc. (N A S D A Q: ZENA) Multi-Industry Vision in the Spotlight
A Landmark October 30th FDA Approval, Commercial Manufacturing Readiness, Two-Year Stability Results, and an $11.25 Million DARPA Research Contract Put NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) at an Important Turning Point in Its Growth
With Preliminary Q3 Revenue Estimated at Up to C$14.8 Million, 425% First-Half Growth and an Expanding AI Drone Ecosystem, ZenaTech $ZENA Is Building a Bigger Opportunity for Investors
Roche Diagnostics $RHHBY Collaboration, Promising REQORSA® Biomarker Research, and Expanding Gene Therapy Programs Put Genprex $GNPX in the Spotlight
$CYCU Boasts a 30 Million Annual Run Rate After Signing Largest Contract Ever, Valued Over $54 Million
Eagle Springs has restarted with a 5,000-barrel-per-day capacity, a proposed $50 million non-dilutive Nevada oil initiative and a substantial Utah resource opportunity, Sky Quarry $SKYQ is advancing its vision of a more integrated Western U.S. energy plat
With relationships spanning 600 telecommunications operators, a potential reach of 2.3 billion end users, and fresh momentum in mobile entertainment, IQSTEL is advancing its strategy to transform a substantial telecommunications platform into a higher-mar
NRXP Reports Three Successfully Manufactured Commercial Lots, Two-Year Stability Data, and Commercially Releasable Supply Pending FDA Approval — While an $11.18 Million DARPA Contract Expands the Company's Research Opportunities
October 15 FDA Update Confirms Minor Labeling Changes Ahead of November 10 Goal Date, While an $11.18 Million DARPA Contract and Innovative Depression Research Expand the Company's Potential
New Meta META Reseller Status, Expanding Consumer Demand and Emerging Applications Across Humanoid Robotics, Military Training and Healthcare Position Virtuix $VTIX at the Intersection of Immersive Technology and Next-Generation Innovation
From "Diagnose and Treat" to "Predict, Alert and Intervene"—POMDOCTOR $POM. New AI-Powered Predictive Healthcare Vision Takes Center Stage in October 12 Announcement.
New SmallCapVoice interview with $SKYQ puts the spotlight on a restarted Nevada refinery, 5,000-barrel-per-day potential, a non-dilutive $50 million oil-development initiative and Sky Quarry's plans to ramp both Nevada and Utah operations.
From AI-Powered Chronic Disease Management to "Hardware + AI + Payment," POMDOCTOR Is Building a Broader Digital Healthcare Infrastructure Platform
Today's landmark defense contract launches the FDA-approved SPARC-TMS trial while NRx simultaneously advances its preservative-free ketamine program, HOPE Therapeutics and an expanding CNS pipeline
As fentanyl continues to drive an enormous public-health challenge in the United States, Nutriband's AVERSA™ technology is being developed to address a different but important piece of the problem: abuse, misuse, diversion and accidental exposure involvin